We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Local manufacturing sector output in Romania comprises predominantly
cheap, basic medicines, with the market reliant on imports, in particular at
the hi-tech end of the scale.
GlaxoSmithKline Pharmaceuticals India (GSK India), the local unit
of the UK drug major, has reiterated its enthusiasm for pursuing new research
partnerships with local drug companies in the wake of the country's new intellectual
property regime, but remains cautious on creating any new marketing alliances
in the country.
Leading drug companies operating in India, including multinational
firms, have welcomed a reduction in import duties from 20% to 15% in the country's
latest budget.
Pakistani officials have mooted the possibility of greater
co-operation with Bangladeshi pharmaceuticals interests as neighbouring India
adopts its new WTO-compliant patent regime.
Brazilian drug regulator Anvisa has insisted that an inflation-linked
retail price rise scheduled to be implemented at the end of the month will be
the only one this financial year.
Although drug multinationals dominate the Russian market in value
terms, very few have opted to manufacture in the country, largely due to an
inhospitable regulatory environment.